CUREGBM & GENA HEALTH PARTNERSHIP
We’re excited to partner with Gena Health. Their clinical intelligence platform creates a direct pathway between patients and trials, which is essential as we scale our sonodynamic therapy programme across Europe. Access to treatment shouldn’t depend on whether a patient happens to know that the right trial exists. CureGBM was founded because that pathway didn’t exist when our father was diagnosed with glioblastoma.
"Working with Gena Health means we're building the infrastructure that connects not just GBM patients, but patients across cancer types, to the trials that could change their outcomes." —
Through this collaboration, Gena Health will work alongside CureGBM to improve how patients and families discover and evaluate treatment pathways, including clinical trials and specialist care options. This includes supporting awareness of emerging approaches such as sonodynamic therapy, where access to up-to-date trial information can make a real difference. CureGBM will also have access to Gena Health’s platform to receive patient enquiries and share educational resources with their community.
"It’s incredibly inspiring to see all the work they are doing to make SDT a reality for patients across Europe, and we a delighted to help play a small role."
We are thrilled to collaborating with Richard, Jane, and the whole CureGBM team as we continue to build tools that make precision cancer treatment options easier to understand, navigate and access. Richard and Jane share a similar story to mine, having also lost a parent to GBM.
About Gena Health
About Gena Health
Gena Health is an agentic workspace for oncologists managing complex cancer cases. It brings fragmented clinical data, guidelines, trials, and literature into a single interface, enabling clinicians to identify options, make decisions, and act. Through one natural language workflow, oncologists can search for relevant trials, interrogate evidence, draft referrals, and share treatment pathways directly with patients.
Gena is built to address two structural constraints in cancer care: fragmented information that limits effective clinical reasoning, and administrative burden that slows execution. The result is faster, more coordinated decision-making, and reduced friction in getting patients to the next step in their care.
For every tomorrow
If our story resonates with you, please share this with someone you know.
Help us bring awareness to the urgent need for better brain tumour treatments and faster access to breakthrough therapies.
Be part of the #curegbm family
